Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma.


Journal Article

Extrahepatic cholangiocarcinoma is a rare malignancy. Despite radical resection, survival remains poor, with high rates of local and distant failure. To clarify the role of radiotherapy with chemotherapy, we performed a retrospective analysis of resected patients who had undergone chemoradiotherapy.A total of 45 patients (13 with proximal and 32 with distal disease) underwent resection plus radiotherapy (median dose, 50.4 Gy). All but 1 patient received concurrent fluoropyrimidine-based chemotherapy. The median follow-up was 30 months for all patients and 40 months for survivors.Of the 45 patients, 33 underwent adjuvant radiotherapy, and 12 were treated neoadjuvantly. The 5-year actuarial overall survival, disease-free survival, metastasis-free survival, and locoregional control rates were 33%, 37%, 42%, and 78%, respectively. The median survival was 34 months. No patient died perioperatively. Patient age

Full Text

Duke Authors

Cited Authors

  • Nelson, JW; Ghafoori, AP; Willett, CG; Tyler, DS; Pappas, TN; Clary, BM; Hurwitz, HI; Bendell, JC; Morse, MA; Clough, RW; Czito, BG

Published Date

  • January 2009

Published In

Volume / Issue

  • 73 / 1

Start / End Page

  • 148 - 153

PubMed ID

  • 18805651

Pubmed Central ID

  • 18805651

Electronic International Standard Serial Number (EISSN)

  • 1879-355X

International Standard Serial Number (ISSN)

  • 0360-3016

Digital Object Identifier (DOI)

  • 10.1016/j.ijrobp.2008.07.008


  • eng